LTC1632232I2 - 4[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrilo druska - Google Patents

4[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrilo druska

Info

Publication number
LTC1632232I2
LTC1632232I2 LTPA2016042C LTPA2016042C LTC1632232I2 LT C1632232 I2 LTC1632232 I2 LT C1632232I2 LT PA2016042 C LTPA2016042 C LT PA2016042C LT PA2016042 C LTPA2016042 C LT PA2016042C LT C1632232 I2 LTC1632232 I2 LT C1632232I2
Authority
LT
Lithuania
Prior art keywords
amino
cyanoethenyl
dimethylphenyl
pyrimidinyl
benzonitrile
Prior art date
Application number
LTPA2016042C
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38091637&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LTC1632232(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from MYPI20043578A external-priority patent/MY169670A/en
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of LTPA2016042I1 publication Critical patent/LTPA2016042I1/lt
Publication of LTC1632232I2 publication Critical patent/LTC1632232I2/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Hybrid Cells (AREA)
LTPA2016042C 2004-09-02 2016-12-20 4[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrilo druska LTC1632232I2 (lt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
MYPI20043578A MY169670A (en) 2003-09-03 2004-09-02 Combinations of a pyrimidine containing nnrti with rt inhibitors
PCT/EP2004/052028 WO2005021001A1 (en) 2003-09-03 2004-09-03 Combinations of a pyrimidine containing nnrti with rt inhibitors
EP05101467 2005-02-25
EP05108086.9A EP1632232B3 (en) 2004-09-02 2005-09-02 Salt of 4[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile

Publications (2)

Publication Number Publication Date
LTPA2016042I1 LTPA2016042I1 (lt) 2017-01-10
LTC1632232I2 true LTC1632232I2 (lt) 2024-09-10

Family

ID=38091637

Family Applications (2)

Application Number Title Priority Date Filing Date
LTPA2016043C LTPA2016043I1 (lt) 2004-09-02 2016-12-20 4[[4-[[4-(2-Cyanoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrilo druska
LTPA2016042C LTC1632232I2 (lt) 2004-09-02 2016-12-20 4[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrilo druska

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTPA2016043C LTPA2016043I1 (lt) 2004-09-02 2016-12-20 4[[4-[[4-(2-Cyanoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrilo druska

Country Status (21)

Country Link
EP (1) EP1632232B3 (lt)
JP (1) JP4912309B2 (lt)
CN (1) CN104586850A (lt)
AT (1) ATE508748T1 (lt)
BR (1) BRPI0514871A (lt)
CY (3) CY1112249T1 (lt)
DK (1) DK1632232T6 (lt)
EA (1) EA013686B1 (lt)
ES (1) ES2371442T7 (lt)
FR (2) FR16C1023I2 (lt)
HK (1) HK1210029A1 (lt)
HU (2) HUS1600061I1 (lt)
IL (1) IL181650A (lt)
LT (2) LTPA2016043I1 (lt)
ME (1) ME01246B (lt)
MX (1) MX2007002595A (lt)
NI (1) NI200700068A (lt)
NO (3) NO340654B1 (lt)
PT (1) PT1632232E (lt)
RS (1) RS51923B2 (lt)
SI (1) SI1632232T1 (lt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
RS52821B2 (sr) * 2006-01-20 2021-07-30 Janssen Sciences Ireland Unlimited Co Dugotrajno tretiranje hiv-infekcije sa tcm278
TWI494133B (zh) 2007-03-14 2015-08-01 Tibotec Pharm Ltd 重組用粉末
NZ610729A (en) 2010-11-19 2015-10-30 Gilead Sciences Inc Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
ES2604405T3 (es) * 2011-04-15 2017-03-06 Emcure Pharmaceuticals Limited Un procedimiento para rilpivirina mejorado
EP2628732A1 (en) 2012-02-20 2013-08-21 Sandoz AG Novel crystalline form of rilpivirine hydrochloride
EP2604593A1 (en) 2011-12-14 2013-06-19 Sandoz AG Polymorph of Rilpivirine hydrochloride and its use as antiviral
WO2013087794A1 (en) 2011-12-14 2013-06-20 Sandoz Ag Polymorph of rilpivirine hydrochloride and its use as antiviral
WO2013153161A2 (en) 2012-04-11 2013-10-17 Sandoz Ag Novel polymorph of rilpivirine hydrochloride
WO2013153162A1 (en) 2012-04-11 2013-10-17 Sandoz Ag Polymorph of rilpivirine hydrochloride
CN103570688B (zh) * 2012-07-19 2016-06-08 中国科学院上海药物研究所 2，5-二氨甲基吡嗪类化合物、其药物组合物、制备方法和用途
GR1008965B (el) * 2015-12-02 2017-02-28 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο σκευασμα που περιλαμβανει δαρουναβιρη και μεθοδος παρασκευης αυτου
RU2616267C1 (ru) * 2016-01-25 2017-04-13 Закрытое Акционерное Общество "БИОКОМ" Твердая лекарственная форма индинавира немедленного высвобождения и способ ее получения
HUE064823T2 (hu) * 2016-10-24 2024-04-28 Janssen Sciences Ireland Unlimited Co Diszpergálható készítmények
EP3645003A4 (en) * 2017-06-30 2021-03-10 VIIV Healthcare Company COMBINATION AND USES AND TREATMENTS THEREOF
CN114392241B (zh) * 2022-01-10 2023-07-25 安徽贝克生物制药有限公司 一种利匹韦林片及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307543B1 (en) * 1998-09-10 2001-10-23 Silicon Image, Inc. Bi-directional data transfer using two pair of differential lines as a single additional differential pair
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
MY169670A (en) * 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
PL208533B1 (pl) * 2002-08-09 2011-05-31 Janssen Pharmaceutica Nv Sposób otrzymywania 4-[[4-[[4-(2-cyjanoetenylo)-2,6-dimetylofenylo]amino]-2-pirymidynylo]amino]benzonitrylu oraz sposób otrzymywania związku pośredniego
WO2004050068A1 (en) * 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
CL2004000192A1 (es) * 2003-02-07 2005-03-18 Janssen Pharmaceutica Nv Uso de compuestos derivados de 2-aminopirimidina para preparar un medicamento para la prevencion de una infeccion por vih relaciones sexuales o un contacto intimo en la pareja.

Also Published As

Publication number Publication date
FR16C1025I1 (fr) 2017-02-03
LTPA2016043I1 (lt) 2017-01-10
NO340654B1 (no) 2017-05-22
CY2016051I1 (el) 2017-07-12
EP1632232A1 (en) 2006-03-08
NO20071745L (no) 2007-04-02
FR16C1023I2 (fr) 2025-11-21
CY2016050I1 (el) 2017-07-12
HUS1600061I1 (hu) 2017-01-30
NO2017065I1 (no) 2017-11-21
CN104586850A (zh) 2015-05-06
ES2371442T3 (es) 2012-01-02
MX2007002595A (es) 2007-04-25
IL181650A (en) 2012-08-30
EA200700536A1 (ru) 2007-08-31
NI200700068A (es) 2016-09-29
SI1632232T1 (sl) 2011-09-30
FR16C1023I1 (fr) 2017-02-03
ATE508748T1 (de) 2011-05-15
HK1210029A1 (en) 2016-04-15
EP1632232B3 (en) 2022-03-30
EA013686B1 (ru) 2010-06-30
DK1632232T6 (da) 2022-04-19
RS51923B2 (sr) 2022-05-31
HUS1600060I1 (hu) 2017-01-30
DK1632232T3 (da) 2011-08-22
NO2017063I1 (no) 2017-11-21
IL181650A0 (en) 2007-07-04
LTPA2016042I1 (lt) 2017-01-10
ES2371442T7 (es) 2022-05-12
RS51923B (sr) 2012-02-29
FR16C1025I2 (fr) 2025-11-21
ME01246B (me) 2013-06-20
JP4912309B2 (ja) 2012-04-11
PT1632232E (pt) 2011-08-02
CY1112249T1 (el) 2015-12-09
BRPI0514871A (pt) 2008-06-24
JP2008511592A (ja) 2008-04-17
EP1632232B1 (en) 2011-05-11

Similar Documents

Publication Publication Date Title
LTC1632232I2 (lt) 4[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrilo druska
NO20050524L (no) Fremgangsmater for fremstillingen av 4-[[4-[[4-(2-cyanoetenyl)-2,6-dimetylfenyl]amino]-2-pyrimidinyl]amino]benzonitril
IL202363A0 (en) Crystalline form of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
IS2689B (is) Kristallað form bis [(E)-7-[4-(4-flúorfenýl)-6-ísóprópýl-2-[metýl(metýlsúlfónýl) amínó]pýrimídin-5-ýl](3R, 5S)-3,5-díhýdroxýhept-6-ensýru] kalsíumsalts
DK1797099T3 (da) Piperidinylamino-thieno[2,3-D]pyrimidinforbindelser
DK1487805T3 (da) Pyrimidinderivater
ATE529412T1 (de) Herbizide pyrimidine
DK1824856T3 (da) 2,4 (4,6)-pyrimidinderivater
ATE462365T1 (de) Marknagel
PL1632232T3 (pl) Sól 4-[[4-[[4-(2-cyjanoetenylo)-2,6-dimetylofenylo]amino]-2-pirymidynylo]amino]benzonitrylu
CR9031A (es) Clorhidrato de 4-((4-((4-2-cianoetenil)-2,6-dimetilfenil)amino)-2-pirimidinil)amino)benzonitrilo
AP2487A (en) Fumarate of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]amino]benzonitrile
NI200700069A (es) Fumarato de 4-((4-((4- (2-cianoetenil)-2,6-dimetilfenil)amino)-2- pirimidinil) amino) benzonitrilo